BMAL1 and neoplasm: Based on our observation that BMAL1-HIF2α heterodimers are more sensitive to suppression by the HIF2α antagonist PT2399 than ARNT-HIF2α heterodimers are, we predicted that suppression of tumor growth by PT2399 would be greater at the time of day when BMAL1 is more active.